KRAS mutation

Explorations Unearth New Potential of KRAS Mutations in Pancreatic Cancer https://t.co/G5fIaMjHOe via @onclive (@marciasgreen)

Impact of KRAS G12D and concurrent mutations on NSCLC outcomes. Our cohort shows 15.6% mKRAS (32, 32, 14% for G12C, G12D and G12V), G12D is associated with female and a lower smoking rate (pack/year). @incanMX @AndresFCardonaZ @Ecaballep https://t.co/YVgxHYVNAZ (@ogarrieta)

Despite the high prevalence of KRAS mutations in pancreatic cancers, a limited number of cases harbor an actionable point mutation. @EileenMOReilly @MSKCancerCenter #pancsm https://t.co/7uqF6ZMfTU (@OncLive)

Interested in the latest in #CARTcelltherapy and treatment of HER2+ #esophagogastriccancer and KRAS-G12 C-mutant #NSCLC? You'll find brief summaries of work by @MSKCancerCenter's @jaeparkmd, @YJanjigianMD, @SteveMaronMD, @rohit_thum, + @KCArbourMD here. https://t.co/GDzcsZ7csG (@MSK_DeptOfMed)

Explorations Unearth New Potential of KRAS Mutations in Pancreatic Cancer @EileenMOReilly @MSKCancerCenter #pcsm https://t.co/ROtIRmXNMy (@OncLive)

Explorations Unearth New Potential of KRAS Mutations in #PancreaticCancer https://t.co/akQ4eEmIq9 Featuring data from #ASCO23 including an early phase KRAS targeted vaccine data in adjuvant setting from Dr. @EileenMOReilly (@Aiims1742)

Latest living guideline update on stage IV NSCLC just published. Listen to Dr. @ns_chd share the new updates - including second-line options for patients with EGFR exon 20 insertions or KRAS G12C mutations - & the rationale in our latest podcast episode https://t.co/yIzwf6akKb (@BrittanyEHarvey)

👀 Check out what’s popular this week in #JCOPO: Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant #NSCLC ➡️ https://t.co/4pghKnMZFP @rohit_thum @RielyMD @KCArbourMD #lcsm (@JCOPO_ASCO)

Cracking KRASG12C across all solid tumors: the new kid on the block for tissue-agnostic precision medicine https://t.co/36kOZ8bPEi... https://t.co/XyNcxEXxRm Now open @MDAndersonNews 👉🏽 a phase 1b trial of Adagrasib in KRAS G12C mutant #PancreaticCancer https://t.co/whJlkT6aXi (@Aiims1742)

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC 💥KEAP1, SMARCA4 and CDKN2A mutations lead to shorter survival in lung cancer patients treated with KRAS-G12C inhibitors (@mvnegrao et al.) @CD_AACR @MDAndersonNews https://t.co/Vh2FY3pluD https://t.co/EvmUncUHrN (@dr_yakupergun)

Commentary on @JCO_ASCO paper Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation @GIcancerDoc @Aiims1742 @DrShubhamPant @TumorBoardTues @MPishvaian Thanks to @cczielinski for invite to write the editorial @weoncologists @ESMO_Open https://t.co/erYeW4KdD0 (@VivekSubbiah)

Great paper from @rohit_thum and @KCArbourMD from @MSK_DeptOfMed @MSKCancerCenter Shows a couple of key findings for patients with KRAS G12C mutated NSCLC treated with sotorasib. https://t.co/QOhzCq4z9i @JCOPO_ASCO (@RielyMD)

Are you ready for targeted neoadjuvant therapy for EGFR and KRAS G12C mutant NSCLC? @MNagasaka and @kamarroneMD discuss ongoing trials with these new treatment paradigms. More discussion to come later in the program! #DAVAHawaiiLung https://t.co/CSNPUHba3j (@KE_Gallaway)

📢 Pleased to share this link 👇👇 that give you free access to our article "Severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti-PD(L)1 and sotorasib therapy in KRASG12C-mutant lung cancer" @JTOonline https://t.co/ag88PwcEVL (@MDuruisseaux)

WATCH: @DrShubhamPant, of @MDAndersonNews, discusses the investigation of adagrasib in the treatment of patients with KRAS G12C–mutated advanced solid tumors. #crcsm https://t.co/H1vDezOWOg (@OncLive)

#ILCC23 what to do at the time of PD from acquired resistance in oncogene-driven NSCLC? Empiric or biomarker-related decision making? Is paradigm different for EGFR-mutated vs ALK vs METex14 vs KRAS G12C? Come listen to our panel discussion @HwakeleeMD @DrRoyHerbstYale @gotoPER (@drgandara)

Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS G12C Mutated Non–Small-Cell Lung Cancer Who Have Untreated CNS Metastases @JCO_ASCO #Precisionmedicine https://t.co/hDyyoGFtXh (@VivekSubbiah)

Si te perdiste #ASCO23, ya tienes disponibles los video-resúmenes de #LungCancer Updates de la mano del @gecp_org. En este caso, el Dr. @NadalErnest aborda las novedades en: ▶️ CPNM KRAS mutado https://t.co/v78bHIhbjh ▶️ CPNM Driver negativo https://t.co/J68BovSEKp #ASCOUPDATES (@SECTtoracica)

The Role of Driver Mutations in NSCLC Treatment - 2022 Program: LCVL https://t.co/UeZfcTFXBI In this video, Dr. @JackWestMD discusses driver mutations such as KRAS and ALK, and the importance of advocating for targeted therapy for patients with actionable mutations. (@cancerGRACE)

BI-2493 / BI-2865: non-covalent inhibitors, binding the inactive state of KRAS, blocked the activation of wild-type KRAS and a broad range of KRAS mutants, including G12A/C/D/F/V/S, G13C/D, V14I, L19F, Q22K, D33E, Q61H, K117N and A146V/T. @Boehringer #LCSM https://t.co/7m549MX20c (@HHorinouchi)

@DrShubhamPant, a member of our Conquering KRAS in Pancreatic Cancer TeamLab, presented Updates on Abstract 425082: Krystal-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Advanced Solid Tumors Harboring a KRASG12C Mutation. (@break_cancer)

@AACR @CCR_AACR 🚨 📚: Early ctDNA changes of KRAS G12C in Phase 2 trial of adagrasib 🧪 for advanced #KRASG12C mutant #LCSM 🩺. @KRASKickers Max response seen in first ~3 weeks 🕐. 89.7% patients showed >90% ctDNA decrease 📉 84.6% achieved complete clearance by cycle 2 🧪.… https://t.co/NPwRU31v6L (@ADesaiMD)

In a session on #LungCancer at #ASCO23, @LuisPaz_Ares shares biomarker analyses of CodeBreaK 200, a phase 3 trial of investigating pretreated KRAS G12C-mutated advanced #NSCLC: https://t.co/aVVKyvGlF4 #CRUKFunded (@CRUKresearch)

Always a treat to hear @Aiims1742 describe RAS signalling and differences in KRAS mutant alleles in #PancreaticCancer pathogenesis ➡️ integration of transcriptomics to interrogate TME and metabolomics #abstract4020 ✅ Differences certainly in G12D vs G12R (@graokane)

Destiny -CRC02 Trastuzumab deruxtecan in CRC . For both k ras mutated and wild type . 5.4 mg per kg dose better tolerated Will it make it big in CRC ? @agrothey @GIcancerDoc @MPishvaian @asco @OncoAlert #ASCO23 (@SuyogCancer)

Phase 1 Study of NEROFE and doxorubicin in KRAS-mutated ST2- positive solid tumors (TPS2667). @benweinbergmd @chulkimMD @RuthHe12 @mnoel3232 @StephenVLiu @LombardiCancer (@RueschCenter)

In a first-in-human Phase I study, Dr. Maria Pia Morelli evaluated the safety and efficacy of the Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors (2547).https://t.co/jfW7BFjeFH @mariapiamorell1 @skopetz @ASCO #ASCO23 #EndCancer (3/9) (@MDAndersonNews)

#KRAS VACCINE strategy may have a possible broad applicability in solid tumors due to KRAS mutational frequency AMPLIFY-201 #ASCO23 @pashtoonkasi (@alfdestefano)

"I'm hopeful this is the decade where we finally crack the KRAS code," says Dr. Shubham Pant in his presentation at #ASCO23 about a study he led on adagrasib use in patients with advanced solid tumors with a KRAS mutation. https://t.co/PUUSItVLBL @ASCO @DrShubhamPant #EndCancer (@MDAndersonNews)

The second @ASCO abstract from @benweinbergmd is "Phase I study of NEROFE and doxorubicin in KRAS-mutated ST2-positive solid tumors." This found that NEROFE also has been shown to induce microRNA miR-217 which downregulates KRAS and MAPK1/2 gene expression in preclinical models.… https://t.co/GqgfaJC5tj (@CCAlliance)

AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P #immunotherapy for patients with high-relapse risk with #KRAS G12D- or G12R-mutated pancreatic and colorectal cancer. @EileenMOReilly #ASCO23 #ASCO2023 #clinicaltrials #news https://t.co/ITEzfo6nRF (@imedverse)

There’s going to be a lot of activity in the adjuvant space in #PancreaticCancer with different vaccine platforms & immune modulators. There’s a real potential here to delay or prevent recurrences. Hopefully we can expand beyond mutant KRAS/p53 as target antigens. #ASCO23 (@Aiims1742)

Abstract 2528: AMPLIFY-201, a 1st-in-human safety & efficacy trial of adjuvant ELI-002 immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated #PancreaticCancer & #ColorectalCancer. @EileenMOReilly & @DrShubhamPant 👉🏽 non-mRNA vaccine in adjuvant space. (@Aiims1742)

4/ #ASCO23 Abs9006 #LCSM 💡SCARLET: ✅ Sotorasib + platinum-doublet chemo shows promising results in chemo-naive, adv non-squamous NSCLC pts w/ KRAS G12C mutation (jRCT2051210086). 🔥 ORR: 88.9%, 6-mo PFS: 61.2%, 6-mo OS: 87%. ⚠️ AE: Mostly manageable hematological toxicities.… https://t.co/xTQFTNwxbf (@ADesaiMD)

Our experts will present their latest research at #ASCO23, including studies of acute lymphoblastic leukemia, KRAS G12C-mutated tumors and racial disparities in GI cancers. Learn about them here: https://t.co/PUUSItVLBL @DrShubhamPant @ColonCancerDoc @ASCO #EndCancer (@MDAndersonNews)

This KRAS mutant #colorectalcancer survivor is also excited to see everyone at #ASCO23 🤗 (@stacy_hurt)

Interesting findings which confirm retrospectively the increase risk of severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti-PD(L)1 and sotorasib therapy in KRASG12C-mutant lung cancer ⁦@JTOonline⁩ https://t.co/FliPTNynCM (@LuisLara_M)

Getting great information from @Benjohnson1112 about what is new in young onset #colorectalcancer from an oncology perspective! ✅YOCRC biology differs based on race and sex ✅No significant difference in KRAS, NRAS mutations in YOCRC #crcsm #ayacsm #cancer @MDAndersonNews (@ARosen380)

📢 Our work just out @JTOonline "Severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti-PD(L)1 and sotorasib therapy in KRASG12C-mutant lung cancer" @OncoAlert @IASLC @OncBrothers https://t.co/fyOITTqHpz (@MDuruisseaux)

40 M, met colon cancer, right sided On Folfox + bev NGS with BRCA2 + KrasG12D mutation No trial available Upon progression Tx? Of Label PARP? FOLFIRI+ Bev/Rami Other? (@BijoyTelivala)

Our clinical trial of Adagrasib in KRAS G12C mutant #PancreaticCancer is open & enrolling at @MDAndersonNews. It is led by Dr. @DanZhaoMD and will be accompanied by extensive tissue & blood based correlatives. @DrShubhamPant @break_cancer @letswinpc https://t.co/gPUKFejyck (@Aiims1742)

🔥🔥🔥Less than a month from ➡️@ASCO Plenary presentation ➡️@JCO_ASCO publication #Adagrasib is part of the @NCCN guidelines for patients with #PancreaticCancer and 🎯 #KRAS G12C mutation (@DrShubhamPant)